CO2023000415A2 - Gel vaginal - Google Patents

Gel vaginal

Info

Publication number
CO2023000415A2
CO2023000415A2 CONC2023/0000415A CO2023000415A CO2023000415A2 CO 2023000415 A2 CO2023000415 A2 CO 2023000415A2 CO 2023000415 A CO2023000415 A CO 2023000415A CO 2023000415 A2 CO2023000415 A2 CO 2023000415A2
Authority
CO
Colombia
Prior art keywords
vaginal gel
composition
gel
terconazole
useful
Prior art date
Application number
CONC2023/0000415A
Other languages
English (en)
Inventor
Robert J Borgman
James E Juul
Original Assignee
Nat Medical Supply Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Medical Supply Llc filed Critical Nat Medical Supply Llc
Publication of CO2023000415A2 publication Critical patent/CO2023000415A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

Una composición que tiene una consistencia de tipo gel contiene metronidazol, terconazol, un espesante fisiológicamente aceptable y agua. La composición es útil para tratar la vaginosis bacteriana así como la candidiasis vulvovaginal.
CONC2023/0000415A 2020-06-18 2023-01-13 Gel vaginal CO2023000415A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/904,678 US11529346B2 (en) 2020-06-18 2020-06-18 Vaginal gel
PCT/US2021/028631 WO2021257179A1 (en) 2020-06-18 2021-04-22 Vaginal gel

Publications (1)

Publication Number Publication Date
CO2023000415A2 true CO2023000415A2 (es) 2023-01-26

Family

ID=79022797

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0000415A CO2023000415A2 (es) 2020-06-18 2023-01-13 Gel vaginal

Country Status (14)

Country Link
US (1) US11529346B2 (es)
EP (1) EP4167964A4 (es)
JP (1) JP2023531443A (es)
KR (1) KR20230026456A (es)
CN (1) CN115955967A (es)
AR (1) AR122687A1 (es)
AU (1) AU2021292945A1 (es)
BR (1) BR112022025861A2 (es)
CA (1) CA3182553A1 (es)
CO (1) CO2023000415A2 (es)
IL (1) IL299066A (es)
MX (1) MX2022016348A (es)
TW (1) TW202214247A (es)
WO (1) WO2021257179A1 (es)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837378A (en) * 1986-01-15 1989-06-06 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
US5536743A (en) 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
FR2777783A1 (fr) 1998-04-24 1999-10-29 Innothera Lab Sa Association pharmaceutique d'imidazoles pour le traitement local des vulvo-vaginites infectieuses et des vaginoses
US20030130225A1 (en) * 2001-10-16 2003-07-10 Nawaz Ahmad Novel methods of treating local fungal and bacterial infections
US6899890B2 (en) * 2002-03-20 2005-05-31 Kv Pharmaceutical Company Bioadhesive drug delivery system
US20040151774A1 (en) * 2002-10-31 2004-08-05 Pauletti Giovanni M. Therapeutic compositions for drug delivery to and through covering epithelia
US6913759B2 (en) * 2003-03-11 2005-07-05 Curatek Pharmaceuticals Holding, Inc. Gel composition and method for treatment of vaginal infections
GB0405406D0 (en) * 2004-03-10 2004-04-21 Edko Pazarlama Tanitim Ltd Sti Anti-vaginitis compositions
US20060093675A1 (en) * 2004-10-29 2006-05-04 Mathew Ebmeier Intravaginal treatment of vaginal infections with metronidazole compositions
US8258164B2 (en) * 2006-09-12 2012-09-04 Curatek Pharmaceuticals Holding, Inc. Nitroimidazole composition and method
US10398692B2 (en) 2006-09-12 2019-09-03 Curatek Pharmaceuticals Holding, Inc. Terconazole composition and method
US20080063668A1 (en) * 2006-09-12 2008-03-13 Borgman Robert J Nitroimidazole and terconazole composition and method
CN103536592B (zh) * 2013-10-11 2015-04-08 哈尔滨欧替药业有限公司 甲硝唑呋喃唑酮阴道膨胀栓及其制备方法和检测方法
ITRM20130690A1 (it) * 2013-12-17 2015-06-18 Over S R L Composizioni per il trattamento topico delle infezioni da gardnerella vaginalis
EP3388063A1 (en) * 2017-04-14 2018-10-17 Adamed sp. z o.o. Treatment of a bacterial vaginal infection

Also Published As

Publication number Publication date
CA3182553A1 (en) 2021-12-23
US20210393619A1 (en) 2021-12-23
KR20230026456A (ko) 2023-02-24
WO2021257179A1 (en) 2021-12-23
TW202214247A (zh) 2022-04-16
US11529346B2 (en) 2022-12-20
MX2022016348A (es) 2023-03-06
JP2023531443A (ja) 2023-07-24
AU2021292945A1 (en) 2023-02-16
EP4167964A4 (en) 2024-07-17
EP4167964A1 (en) 2023-04-26
BR112022025861A2 (pt) 2023-03-14
AR122687A1 (es) 2022-09-28
IL299066A (en) 2023-02-01
CN115955967A (zh) 2023-04-11

Similar Documents

Publication Publication Date Title
BR112017011067A2 (pt) cepas e métodos para a partição de energia em ruminantes
PE20211700A1 (es) Compuesto heterociclico y su uso
CL2017000998A1 (es) Composición que comprende un agente de control biológico de la especie bacillus subtilis y un fungicida del grupo de inhibidores de la mitosis y la división celular, tal como fenamidona. (divisional solicitud 3272-2014)
AR061772A1 (es) Composicion de alto contenido de ion fluoruro para el cuidado oral y metodo para mantener la actividad anticaries
DOP2012000245A (es) Composiciones sólidas
UY29086A1 (es) Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos.
PA8588601A1 (es) Administracion combinada de una indolinona junto a un agente quimioterapeutico para el tratamiento de enfermedades de proliferacion celular
CL2011001177A1 (es) Formulacion inyectable que comprende ceftiofur, alcohol bencilico, propilenglicol, un agente humectante y aceite de semilla de algodon.
AR083651A1 (es) Composiciones de brimonidina en gel y metodos de uso
MY170013A (en) Methods and compositions for enhancing stem cell mobilization
ES2571956T3 (es) Uso médico de la alfa 1-microglobulina antioxidante y eliminadora de radicales
CO2021011685A2 (es) Método de diseño de polímeros para un control eficaz de la pérdida de fluido
AR100329A1 (es) Composición y método para el cuidado oral
NZ709209A (en) Internal ultrasound gel
CO2023000415A2 (es) Gel vaginal
CL2022002148A1 (es) Inhibidores heterocíclicos de pad4
CO2021016775A2 (es) Método de riego que utiliza hidrogeles en el suelo para extraer agua de la atmosfera
CL2023003086A1 (es) Composiciones y métodos para reducir los hla-a en una célula
EA201490881A1 (ru) Органогель, структурированный 12-hsa и выбранным сополимером
AR067738A1 (es) Fluido aislante anular
NZ591741A (en) Benzimidazole anthelmintic compositions
AR043044A1 (es) Composicion antihelmintica
MD2516C2 (ro) Remediu medicamentos antiinflamator, antiseptic şi antifungic sub formă de gel
CL2007001794A1 (es) Compuestos derivados de 2-imidazolidinona, inhibidores del canal de potasio kv1.5; composicion farmaceutica que los comprende; y su uso para tratar o prevenir arritmias cardiacas. tromboembolia,apoplejia,insuficiencia cardiaca.
AR107169A1 (es) Un método para la manufactura de un anillo vaginal